Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Not Confirmed
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Not Confirmed
Not Confirmed
05-08 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Industry Trade Show
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Industry Trade Show
Not Confirmed
05-08 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
02 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302573337.html
25 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302566500.html
25 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302536840.html
12 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/inovio-reports-second-quarter-2025-financial-results-and-recent-business-highlights-302528176.html
11 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/data-published-in-the-laryngoscope-shows-ino-3107-resulted-in-long-term-surgery-reduction-in-recurrent-respiratory-papillomatosis-rrp-302526066.html
04 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/inovio-to-report-second-quarter-2025-financial-results-on-august-12-2025-302520939.html
Details:
The net proceeds will be used for the development and a potential commercial launch of INO-3107 if approved.
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Piper Sandler
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 03, 2025
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Piper Sandler
Deal Size : $25.0 million
Deal Type : Public Offering
INOVIO Announces Pricing of $25 Million Public Offering
Details : The net proceeds will be used for the development and a potential commercial launch of INO-3107 if approved.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 03, 2025
Details:
The net proceeds will be used for the development and a potential commercial launch of INO-3107 if approved.
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 02, 2025
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Piper Sandler
Deal Size : Undisclosed
Deal Type : Public Offering
INOVIO Announces Proposed Public Offering
Details : The net proceeds will be used for the development and a potential commercial launch of INO-3107 if approved.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 02, 2025
Details:
Synthetic DNA plasmids encoding AZD5396 and AZD8076 (derived from cilgavimab and tixagevimab) delivery via CELLECTRA 2000 electroporation device, is being investigated in covid 19 patients.
Lead Product(s): AZD5396,AZD8076
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Recipient: AstraZeneca
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : AZD5396,AZD8076
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Inovio Reports Positive Interim Results for DMAbs in Covid-19 Proof-Of-Concept Trial
Details : Synthetic DNA plasmids encoding AZD5396 and AZD8076 (derived from cilgavimab and tixagevimab) delivery via CELLECTRA 2000 electroporation device, is being investigated in covid 19 patients.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 17, 2025
Details:
The net proceeds will be used to fund the clinical advancement of the comanpany's lead product INO-3107, which is being evaluated for treating recurrent respiratory papillomatosis.
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Oppenheimer & Co. Inc.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2024
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Oppenheimer & Co. Inc.
Deal Size : $30.0 million
Deal Type : Public Offering
INOVIO Announces Pricing of $30 Million Public Offering
Details : The net proceeds will be used to fund the clinical advancement of the comanpany's lead product INO-3107, which is being evaluated for treating recurrent respiratory papillomatosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 13, 2024
Details:
The net proceeds will be used to fund the clinical advancement of the comanpany's lead product INO-3107, which is being evaluated for treating recurrent respiratory papillomatosis.
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Oppenheimer & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 12, 2024
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Oppenheimer & Co. Inc.
Deal Size : Undisclosed
Deal Type : Public Offering
INOVIO Announces Proposed Public Offering
Details : The net proceeds will be used to fund the clinical advancement of the comanpany's lead product INO-3107, which is being evaluated for treating recurrent respiratory papillomatosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 12, 2024
Details:
INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2024
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
INO-3107 Achieves Complete Response in Half Of RRP Patients Over 2-3 Years
Details : INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 03, 2024
Details:
INO-3107 is an investigational DNA medicine designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins.
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 13, 2024
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
INOVIO Shows INO-3107 Reduces Surgeries for RRP with T Cell Expansion in Phase 1/2
Details : INO-3107 is an investigational DNA medicine designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 13, 2024
Details:
INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 25, 2024
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inovio Receives Advanced Therapy Certificate from EMA for INO-3107 Data
Details : INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 25, 2024
Details:
INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Lead Product(s): INO-3107,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 11, 2024
Lead Product(s) : INO-3107,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
INO-3107 Awarded Innovation Passport in UK for Innovative Licensing Pathway
Details : INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 11, 2024
Details:
The collaboration aims to evaluate INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for locoregionally advanced, high-risk HPV16/18 positive oropharyngeal squamous cell carcinoma.
Lead Product(s): INO-3112,Toripalimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Vaccine
Sponsor: Coherus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Lead Product(s) : INO-3112,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Coherus Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
INOVIO and Coherus Collaborate On INO-3112 with LOQTORZI™ (toripalimab-tpzi)
Details : The collaboration aims to evaluate INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for locoregionally advanced, high-risk HPV16/18 positive oropharyngeal squamous cell carcinoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2024
ABOUT THIS PAGE